Abstract
Rationale The coronary microvasculature is crucial for proper cardiac function, and coronary microvascular disease (CMVD) has emerged as an underdiagnosed and undertreated cause of ischemic heart disease. Friend of GATA 2 (FOG2) is a transcriptional co-regulator crucial for coronary development and the maintenance of the coronary microvasculature in adult mice.Little is known about the role of FOG2 in humans or its role in CMVD.
Objective Here, we report a genotype-first approach to determine the role of FOG2 in human coronary microvascular disease.
Findings We performed Phenome-Wide association studies and deep cardiac phenotyping through the Electronic Health record in patients with FOG2 coding variants and identified an association between rs28374544 (A1969G, S657G) and CMVD. Patients with S657G had increased chest pain, smaller burden of obstructive coronary artery disease, and altered coronary blood flow. Differential gene and pathway analysis using several genomic datasets showed that carriers of S657G have increased expression of genes involved in angiogenesis, glycolysis, and the hypoxia-inducible factor (HIF) pathway. In vitro functional studies show that FOG2 S657G promotes angiogenic gene expression and angiogenesis while decreasing oxygen consumption rate. FOG2 also regulates HIF1a occupancy of angiogenic genes.
Conclusions We identified a human missense variant which is associated with CMVD and established a potential mechanism by which the variant may altered angiogenic gene expression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.G. is supported by NHLBI K08 and Burroughs Wellcome Fund. The Penn Medicine Biobank is supported by Perelman School of Medicine at University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA award number UL1TR001878.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Pennsylvania gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of interest statement: The authors have declared that no conflict of interest exists.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
